Cansino Biologics Sustainability Profile
Cansino Biologics Inc., commonly referred to as Cansino, is a prominent biopharmaceutical company headquartered in China (CN). Founded in 2009, the company has established itself as a leader in the development of innovative vaccines and biologics, with a strong focus on addressing global health challenges. Cansino operates primarily in the fields of vaccine research and development, particularly in the areas of infectious diseases and oncology. The company gained significant recognition for its pioneering work on the Ad5-nCoV vaccine, which was one of the first COVID-19 vaccines to receive emergency use authorisation. Cansino's unique adenoviral vector platform sets it apart in the industry, enabling rapid development and deployment of vaccines. With a robust pipeline and strategic partnerships, Cansino Biologics continues to solidify its position as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Cansino Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cansino Biologics's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cansino Biologics's reported carbon emissions
In 2024, Cansino Biologics reported total greenhouse gas emissions of approximately 31,075,310 kg CO2e, encompassing Scope 1, 2, and 3 emissions. The breakdown includes Scope 1 emissions of about 1,686,800 kg CO2e, primarily from stationary combustion (1,176,730 kg CO2e) and fugitive emissions (668,610 kg CO2e). Scope 2 emissions from purchased steam totalled approximately 11,725,300 kg CO2e, while Scope 3 emissions, mainly from waste generated in operations, reached about 221,993,220 kg CO2e. In 2023, the company reported total emissions of approximately 37,294,900 kg CO2e, with Scope 1 emissions at about 2,336,900 kg CO2e and Scope 2 emissions at approximately 14,064,580 kg CO2e. Scope 3 emissions for that year were approximately 19,689,150 kg CO2e. Cansino Biologics has set ambitious reduction targets, aiming for a 40% reduction in total greenhouse gas emissions per floor area by 2025, using 2021 as the baseline. Furthermore, the company plans to achieve a 50% reduction by 2030 for both Scope 1 and Scope 2 emissions. The emissions data is sourced directly from Cansino Biologics Inc. and is not cascaded from any parent organization. The company is committed to enhancing its sustainability practices and reducing its carbon footprint in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 4,609,750 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 10,386,950 | 00,000,000 | - | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
How Carbon Intensive is Cansino Biologics's Industry?
How Carbon Intensive is Cansino Biologics's Location?
Cansino Biologics's Scope 3 Categories Breakdown
Cansino Biologics's Scope 3 emissions, which increased significantly last year and increased by approximately 803% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Waste Generated in Operations" being the largest emissions source at 93% of Scope 3 emissions.
Top Scope 3 Categories
Cansino Biologics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cansino Biologics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
